COX-2, NSAIDs, and cardiovascular risk

Patricia McGettigan*, David Henry

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.

Original languageEnglish
Pages (from-to)296-302
Number of pages7
JournalCurrent Cardiovascular Risk Reports
Volume1
Issue number4
DOIs
Publication statusPublished - 2007
Externally publishedYes

Fingerprint Dive into the research topics of 'COX-2, NSAIDs, and cardiovascular risk'. Together they form a unique fingerprint.

  • Cite this